Drug Eluting Stents: an Updated Meta-analysis of Randomised Controlled Trials

Overview

Journal Heart

Date 2005 Oct 12

PMID 16216853

Citations 50

Authors

C Roiron

P Sanchez

A Bouzamondo

P Lechat

G Montalescot

Affiliations

Soon will be listed here.

Abstract

Objective: To confirm the overall benefit of drug eluting stents (DES), to evaluate the effect of different DES, and to assess the global safety of DES compared with bare stents through a meta-analysis of randomised controlled trials.

Methods: Randomised controlled trials comparing sirolimus and derivates or paclitaxel and derivates eluting stents versus bare stents. Binary restenosis and major adverse cardiac events (MACE) were chosen as primary end points. Death, Q wave myocardial infarction (MI), and stent thrombosis up to 12 months' follow up were also analysed.

Results: MACE overall occurrence was highly reduced with DES from 19.9% to 10.1% (odds ratio (OR) 0.46, 95% confidence interval (CI) 0.41 to 0.52, p < 0.001). A significant heterogeneity (p < 0.001) was found between subgroups according to the drug: MACE OR was 0.28 (95% CI 0.22 to 0.35) in the sirolimus subgroup and 0.62 (95% CI 0.53 to 0.73) in the paclitaxel subgroup. Restenosis was also highly reduced from 31.7% with bare stents to 10.5% with DES (OR 0.25, 95% CI 0.22 to 0.29, p < 0.001) with a similar heterogeneity between subgroups. Mortality, Q wave MI, and stent thrombosis were not significantly different between DES and control group, whereas Q wave MI and stent thrombosis tended to be more frequent with paclitaxel.

Conclusion: This meta-analysis confirms the overall benefit of DES on restenosis and MACE with significant heterogeneity between drugs, suggesting higher efficacy of sirolimus eluting stents. Additional data with longer follow up and in high risk populations are needed to clarify issues on stent thrombosis.

Citing Articles

Platelet-inspired targeting delivery for coronary heart disease.

Jiang Y, Wei Z, Song Z, Qian H Heliyon. 2024; 10(5):e27166.

PMID: 38449604 PMC: 10915553. DOI: 10.1016/j.heliyon.2024.e27166.

Long-term Outcomes for Drug-eluting Balloons versus Drug-eluting Stents in the Treatment of Small Vessel Coronary Artery Disease: A Systematic Review and Meta-analysis.

Murphy G, Naughton A, Durand R, Heron E, McCaughey C, Murphy R Interv Cardiol. 2023; 18:e14.

PMID: 37398872 PMC: 10311399. DOI: 10.15420/icr.2022.26.

An Update on Drug-eluting Technology in Peripheral Arteries to Treat Peripheral Arterial Disease.

Marques L, Hopf-Jensen S, Preiss M, Mueller-Huelsbeck S Heart Int. 2022; 15(2):73-78.

PMID: 36277826 PMC: 9524588. DOI: 10.17925/HI.2021.15.2.73.

The long-term impact of a chronic total occlusion in a non-infarct-related artery on acute ST-segment elevation myocardial infarction after primary coronary intervention.

Liu Y, Wang L, Yang X, Lu C, Li K, Chen M BMC Cardiovasc Disord. 2021; 21(1):59.

PMID: 33516191 PMC: 7847020. DOI: 10.1186/s12872-021-01874-1.

Toward Brief Dual Antiplatelet Therapy and P2Y12 Inhibitors for Monotherapy After PCI.

Ayoub A, Ayinapudi K, Al-Ogaili A, Panhwar M, Dakkak W, LeJemtel T Am J Cardiovasc Drugs. 2020; 21(2):153-163.

PMID: 32780215 DOI: 10.1007/s40256-020-00430-0.

References

Degertekin M, Regar E, Tanabe K, Smits P, van der Giessen W, Carlier S . Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol. 2003; 41(2):184-9. DOI: 10.1016/s0735-1097(02)02704-3. View

de la Torre Hernandez J, Sainz Laso F, Ruisanchez C, Zueco J, Figueroa A, Colman T . [Treatment of lesions with a high risk of stenosis. Comparative study in 300 patients of rapamycin- and Paclitaxel-eluting polymer-based stents, and bare metal stents]. Rev Esp Cardiol. 2005; 58(3):262-9. View

Kastrati A, Dibra A, Eberle S, Mehilli J, de Lezo J, Goy J . Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA. 2005; 294(7):819-25. DOI: 10.1001/jama.294.7.819. View

Sousa J, Serruys P, Costa M . New frontiers in cardiology: drug-eluting stents: Part I. Circulation. 2003; 107(17):2274-9. DOI: 10.1161/01.CIR.0000069330.41022.90. View

Pan M, de Lezo J, Medina A, Romero M, Segura J, Pavlovic D . Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy. Am Heart J. 2004; 148(5):857-64. DOI: 10.1016/j.ahj.2004.05.029. View

Park S, Shim W, Ho D, Raizner A, Park S, Hong M . A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003; 348(16):1537-45. DOI: 10.1056/NEJMoa021007. View

Stone G, Ellis S, Cox D, Hermiller J, OShaughnessy C, Mann J . A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004; 350(3):221-31. DOI: 10.1056/NEJMoa032441. View

Fischman D, Leon M, Baim D, Schatz R, Savage M, Penn I . A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994; 331(8):496-501. DOI: 10.1056/NEJM199408253310802. View

Lansky A, Costa R, Mintz G, Tsuchiya Y, Midei M, Cox D . Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation. 2004; 109(16):1948-54. DOI: 10.1161/01.CIR.0000127129.94129.6F. View

10.

Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A . Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA. 2004; 292(22):2727-34. DOI: 10.1001/jama.292.22.2727. View

11.

Holmes Jr D, Leon M, Moses J, Popma J, Cutlip D, Fitzgerald P . Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004; 109(5):634-40. DOI: 10.1161/01.CIR.0000112572.57794.22. View

12.

Hoye A, Lemos P, Arampatzis C, Saia F, Tanabe K, Degertekin M . Effectiveness of the sirolimus-eluting stent in the treatment of patients with a prior history of coronary artery bypass graft surgery. Coron Artery Dis. 2004; 15(3):171-5. DOI: 10.1097/00019501-200405000-00006. View

13.

Sousa J, Costa M, Abizaid A, Rensing B, Abizaid A, Tanajura L . Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001; 104(17):2007-11. DOI: 10.1161/hc4201.098056. View

14.

Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T . Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation. 2004; 109(6):701-5. DOI: 10.1161/01.CIR.0000116202.41966.D4. View

15.

Ong A, Hoye A, Aoki J, van Mieghem C, Rodriguez Granillo G, Sonnenschein K . Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol. 2005; 45(6):947-53. DOI: 10.1016/j.jacc.2004.09.079. View

16.

Stone G, Ellis S, Cox D, Hermiller J, OShaughnessy C, Mann J . One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004; 109(16):1942-7. DOI: 10.1161/01.CIR.0000127110.49192.72. View

17.

Grube E, Silber S, Hauptmann K, Mueller R, Buellesfeld L, Gerckens U . TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003; 107(1):38-42. DOI: 10.1161/01.cir.0000047700.58683.a1. View

18.

Honda Y, Grube E, de la Fuente L, Yock P, Stertzer S, Fitzgerald P . Novel drug-delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation. 2001; 104(4):380-3. DOI: 10.1161/hc2901.094149. View

19.

Schofer J, Schluter M, Gershlick A, Wijns W, Garcia E, Schampaert E . Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003; 362(9390):1093-9. DOI: 10.1016/S0140-6736(03)14462-5. View

20.

Lemos P, Saia F, Hofma S, Daemen J, Ong A, Arampatzis C . Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol. 2004; 43(4):704-8. DOI: 10.1016/j.jacc.2003.12.022. View